Vivos TherapeuticsNASDAQ: VVOS

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q1 2024 Results Conference Call will take place on May 14, 2024 at 5:00 PM ET. Participants include Julie Gannon, Kirk Huntsman, and Brad Amman. Conference Call Participants include Lucas Ward from Ascendiant Capital Markets. The operator will begin the call shortly. Thank you for joining the Vivos Therapeutics First Quarter 2024 Earnings Conference Call. Participants are currently in listen-only mode.

Vivos Therapeutics (NASDAQ:VVOS) informed investors that it expects to achieve positive cash flow from operations by the end of 2024 or the first quarter of 2025 through cost-cutting measures and new revenue strategies. The company, focused on treatments for sleep-related breathing disorders such as obstructive sleep apnea (OSA), reported a 22% decrease in operating expenses, totaling $1.6 billion, during the first quarter compared to the previous year.

Vivos Therapeutics CEO Kirk Huntsman anticipates an increase in healthcare professionals recommending their oral medical devices for obstructive sleep apnea (OSA) following the approval of Medicare reimbursement for their CARE oral medical devices. This approval, announced earlier in the week, allows patients with OSA to use an alternative to continuous positive airway pressure (CPAP).

Vivos Therapeutics (NASDAQ:VVOS) is on track to become cash flow positive by the end of 2024, its CEO revealed in its latest financial update. “Based on our progress to date and our revenue growth efforts for 2024, we continue to anticipate becoming cash flow positive from operations by the end of this year,” CEO Kirk Huntsman told shareholders.

Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript

LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults)), today announced it plans to release its fourth quarter and full year 2023 financial results after market close today, Thursday, March 28, 2024.

Vivos Therapeutics (NASDAQ:VVOS) announced that it has entered into a definitive agreement to immediately exercise an outstanding stock purchase warrant held by an institutional investor to purchase an aggregate of 980,393 shares for approximate proceeds of $4 million. The net proceeds will be used by the medical device company specializing in treatments for sleep-related breathing disorders for general corporate purposes.

Vivos Therapeutics (NASDAQ:VVOS) is well-positioned to increase the adoption of its oral medical devices for the treatment of severe obstructive sleep apnea as patients seek alternatives to continuous positive airway pressure (CPAP).  The company's Vivos CARE oral appliance in November 2023 received US Food and Drug Administration (FDA) approval to treat moderate to severe obstructive sleep apnea in adults along with positive airway pressure and/or myofunctional therapy, as required.

Vivos Therapeutics (NASDAQ:VVOS) told investors it has experienced a surge in interest in the wake of the FDA 510(k) clearance from the US Food and Drug Administration (FDA) for its CARE (Complete Airway Repositioning and/or Expansion) oral medical devices targeting severe obstructive sleep apnea (OSA). The medical technology firm said the groundbreaking clearance, granted on November 28, 2023, marks the first time the FDA has approved an oral appliance for treating moderate and severe OSA in adults, aged 18 and older, complemented by positive airway pressure (PAP) and/or myofunctional therapy.